Brandon W. Fenn

Cooley advised Oyster Point Pharma, a top ophthalmology-focused biopharmaceutical company, on its definitive agreement to be acquired by global healthcare company Viatris. Partners Mika Reiner Mayer, Brandon Fenn, Div Gupta and Ian Nussbaum led the Cooley team advising Oyster Point Pharma.

Cooley advised NerdWallet, a personal finance website and app, on its $150.1 million initial public offering of 8,337,500 shares of Class A common stock, which now trade on the Nasdaq Global Market under the symbol NRDS. Lawyers David Peinsipp, John Sellers and Nicole Orders led the Cooley team advising NerdWallet.

Cooley advised Molecular Partners on its $63.75 million initial public offering of 7,000,000 American depositary shares. Molecular Partners, whose securities now trade on the Nasdaq Global Select Market  under the symbol MOLN, is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics. Partners Div Gupta, Ryan Sansom, Brandon Fenn and John Robertson led the Cooley team.

Cooley advised VectivBio on its $146.6 million initial public offering of 8,625,000 ordinary shares, which includes the full exercise of the underwriters’ option to purchase additional shares. VectivBio, whose securities now trade on the Nasdaq Global Market under the symbol VECT, is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe rare conditions for which there is a significant unmet medical need. Partners Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.

Cooley advised the underwriters on Edgewise Therapeutics’ $202.4 million initial public offering of 12,650,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase additional shares. J.P. Morgan Securities, Goldman Sachs and SVB Leerink acted as joint book-running managers for the offering. Edgewise Therapeutics, whose securities now trade on the Nasdaq Global Market under the symbol EWTX, is a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders. Partners Richard Segal, Div Gupta, Ryan Sansom and Brandon Fenn led the Cooley team.